Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Halozyme TherapeuticsHALO +0.74%92 3-Year ROIIC % is 38.79 as of Dec. 2025, which is 88% above its 10-year median of 20.66. GuruFocus rates HALO with a GF Score™ of 92/100 and a GF Value™ of $91.37 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,322 Biotechnology companies, Halozyme Therapeutics ranks better than 70.57% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Halozyme Therapeutics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 38.79%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Halozyme Therapeutics's 3-Year ROIIC % or its related term are showing as below:
HALO's 3-Year ROIIC % is ranked better than 70.57% of 1322
companies
in the Biotechnology industry
Industry Median: -4.82
vs HALO: 38.79
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Halozyme Therapeutics 3-Year ROIIC % Related Terms
Halozyme Therapeutics 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Halozyme Therapeutics's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HALO vs KYMR, IBRX, PRAX: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Halozyme Therapeutics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Halozyme Therapeutics 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Halozyme Therapeutics's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Halozyme Therapeutics (HALO) has a 3-Year ROIIC % of 38.79 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Halozyme Therapeutics and its competitors. This is 88% above median its historical median of 20.66. According to the industry distribution chart, Halozyme Therapeutics ranks #389 out of 1322 companies in the Biotechnology industry, placing it in the top 29.4%.
Is Halozyme Therapeutics' 3-Year ROIIC % too high?
Halozyme Therapeutics' current 3-Year ROIIC % of 38.79 is 88% above median its 10-year median of 20.66. Based on the distribution chart, Halozyme Therapeutics ranks #389 out of 1322 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Halozyme Therapeutics has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' 3-Year ROIIC % compare to KYMR and IBRX?
According to the Biotechnology industry distribution chart, Halozyme Therapeutics ranks #389 out of 1322 companies for 3-Year ROIIC %. This puts Halozyme Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Halozyme Therapeutics and its competitors. Halozyme Therapeutics's current 3-Year ROIIC % is 38.79, which is 88% above median its own 10-year median of 20.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (HALO) is currently considered Modestly Undervalued. The stock's GF Value™ is $91.37, compared to a current price of $75.62 — trading 17.2% below its estimated fair value. The current 3-Year ROIIC % is 38.79, which is 88% above median its 10-year median of 20.66. Halozyme Therapeutics' overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Halozyme Therapeutics (HALO), the current 3-Year ROIIC % is 38.79 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Halozyme Therapeutics (HALO) Overvalued in 2026?
Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be undervalued.
The current stock price of $75.62 is trading 17.2% below its estimated GF Value™ of $91.37.
GuruFocus considers Halozyme Therapeutics to be Modestly Undervalued.
Key valuation signals for HALO:
3-Year ROIIC %: 38.79 (88% above median its 10-year median of 20.66)
GF Value™: $91.37 vs. price of $75.62 (17.2% below fair value)
No single metric tells the full story. See the HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
92GF Score
Get the complete analysis for HALO
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HALO has been successfully added to your 
